Advertisement

Medical Principles of Intraperitoneal and Intrapleural Chemotherapy

  • Maurie Markman
Part of the Developments in Oncology book series (DION, volume 26)

Abstract

While modeling studies have suggested a major pharmacokinetic advantage for peritoneal cavity drug exposure to certain chemotherapeutic agents when administered by the intraperitoneal route (1), there are both theoretical and practical issues which must be addressed prior to the acceptance of this approach to the management of malignant disease principally confined to the peritoneal or pleural cavities. The importance of establishing a safe and simple method of accessing the abdominal cavity has been discussed in another paper in this symposium.

Keywords

Peritoneal Dialysis Ovarian Carcinoma Pleural Fluid Pleural Cavity Body Cavity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr: Pharmacokinetic rationale for peritoneal administration in the treatment of ovarian cancer. Cancer Treat Rep 62: 1–9, 1978.PubMedGoogle Scholar
  2. 2.
    Katz ME, Schwartz PE, Kapp DS, Luikart S: Epithelial carcinoma of the ovary: current strategies. Ann Intern Med 95: 98–111, 1981.PubMedGoogle Scholar
  3. 3.
    Rosenshein N, Blake D, Mclntyre PA, Parmley T, Natarajan TK, Dvornicky J, Nickoloff E: The effect of volume on the distribution of substances instilled into the peritoneal cavity. Gynecologic Oncol 6: 106–110, 1978.CrossRefGoogle Scholar
  4. 4.
    Tully TE, Goldberg ME, Loken MK: The use of 99mTc-sulfur colloid to assess the distribution of 32P chromic phosphate. J Nucl Med 15: 190–191, 1974. 32PubMedGoogle Scholar
  5. 5.
    Taylor A Jr: Loculation as a contraindication to intracavitary P chromic phosphate therapy. J Nucl Med 16: 318–319, 1975.PubMedGoogle Scholar
  6. 6.
    Howell SB, Pfeifle CE, Wung WE, Olshen RA, Lucas WE, Yon JL, Green MR: Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97: 845–851, 1982.PubMedGoogle Scholar
  7. 7.
    Dunnick NR, Jones RB, Doppman JL, Speyer J, Myers CE: Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. AJR 133: 221–223, 1979.PubMedGoogle Scholar
  8. 8.
    Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC: Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 39: 3209–3214, 1979.PubMedGoogle Scholar
  9. 9.
    King ME, Howell SB: Intraperitoneal cytarabine therapy in ovarian carcinoma. J Clin Oncol (in press), 1983.Google Scholar
  10. 10.
    Alberts DS, Chen HSG, Chang SY, Peng YM: The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. Recent Results in Cancer Res 74: 293 - 299, 1980.Google Scholar
  11. 11.
    Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Green R, Jenkins J, Myers CE: Phase I and pharmacological studies of Adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer 42: 4265–4269, 1982.Google Scholar
  12. 12.
    Gloor HJ, Nichols WK, Sorkin MI, Prowant BF, Kennedy JM, Baker B, Nolph KD: Peritoneal access and related cpmplications in continuous ambulatory peritoneal dialysis. Am J Med 74: 593–598, 1983.PubMedCrossRefGoogle Scholar
  13. 13.
    Rubin J, Rogers WA, Taylor HM, Everett ED, Prowant BF, Fruto LV, Nolph KD: Peritonitis during continuous ambulatory peritoneal dialysis. Ann Intern Med 92: 7–13, 1980.PubMedGoogle Scholar
  14. 14.
    Krothapalli RK, Senekjian HD, Ayus JC: Efficacy of intravenous vancomycin in the treatment of gram-positive peritonitis in long-term peritoneal dialysis. Am J Med 75: 345–348, 1983.PubMedCrossRefGoogle Scholar
  15. 15.
    Wade JC, Schimpff SC, Newman KA, Wiernik PH: Staphlococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med 97: 503–508, 1982.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1984

Authors and Affiliations

  • Maurie Markman

There are no affiliations available

Personalised recommendations